Physician profile
Andrew Stanton
NPI 1427405869
$890.73
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $272 · 2021: $118 · 2022: $342.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $178.07 | 2019-2022 | |
| Novo Nordisk INC | $170.53 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.70 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $73.80 | 2022 | |
| Janssen Pharmaceuticals, INC | $63.65 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $53.97 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $47.06 | 2022 | |
| Daiichi Sankyo INC. | $27.25 | 2019 | |
| Lilly USA, LLC | $24.97 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.24 | 2020 | |
| Lucid Diagnostics INC. | $14.99 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.94 | 2022 | |
| Amgen INC. | $14.56 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.45 | 2021 | |
| Merck Sharp & Dohme LLC | $12.78 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $12.08 | 2020 | |
| Abbvie INC. | $11.69 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Stanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.